Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target raised by analysts at Maxim Group from $3.00 to $12.00. They now have a "buy" rating on the stock.
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm [Yahoo! Finance]Yahoo! Finance
- Lexaria Releases Annual Letter from the CEOAccesswire
- Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Lexaria Bioscience files for $50M mixed securities shelf [Seeking Alpha]Seeking Alpha
- Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board ApprovalAccesswire
LEXX
Sec Filings
- 2/5/25 - Form 8-K
- 2/5/25 - Form 424B5
- 1/31/25 - Form EFFECT
- LEXX's page on the SEC website